Skip to content

Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective

Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective: A Randomized Blinded Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03261622
Acronym
SNS
Enrollment
73
Registered
2017-08-25
Start date
2016-11-01
Completion date
2020-11-01
Last updated
2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Faecal Incontinence, Fecal Incontinence

Keywords

Sacral Nerve Stimulation, Sacral Nerve Modulation

Brief summary

Sacral nerve stimulation (SNS) has over the last 20 years been recognised as an efficient treatment option for faecal incontinence (FI). In a selected patient group we have evidence that 90% of patients will have a successful test period (≥50% reduction in incontinence episodes). If preoperative there is motor response on at least 3 out of 4 poles on the lead, at a threshold ≤1.5 mAMP. Hypotheses In a selected patient group suffering from faecal incontinence a one-stage permanent implant will be possible. The functional results will be improved as more time can be spent finding the optimal pacemaker settings as the risk of infection is reduced compared to the stage implant. One-Stage implantation gives the opportunity to test the amount of placebo effect with SNS. During the first 3 months postoperative patients will be randomized to either stimulation amplitude set at 90% of sensory threshold (control group) or 3 periods of stimulation at 0.05v (placebo), 50% and 90% of sensory threshold. Patients are randomized in a 1 to 2 pattern. After the initial 3 months the stimulation amplitude is increased to sensory threshold. After six months the project ends and the number of patients achieving the 50% improvement in incontinence episodes are evaluated.

Detailed description

Sacral nerve stimulation (SNS) has over the last 20 years been recognised as an efficient treatment option for faecal incontinence (FI). The therapy is recommended by the International Continence Society (ICS) if conservative treatments such as; regulation of diet and fibre supplements, medication, biofeedback therapy, glycerol suppositories, mini enema or transanal irrigation have been insufficient to improve continence to a satisfactory level. The SNS therapy has traditionally been applied as a two step procedure. Firstly, a 3-4 week test-period, often with a permanent electrode with tines, followed by permanent implantation if at least a 50% symptom reduction has been obtained during the test stimulation. In a selected patient group(idiopathic faecal incontinence or incontinence as a result of an external anal sphincter tear (\<160 degrees)) we have evidence that 90% of patients will have a successful test period (≥50% reduction in incontinence episodes). If preoperative there is motor response on at least 3 out of 4 poles on the lead, at a threshold ≤1.5 mAMP(unpublished data, submitted for publication) . Thus, only 10% of the patients have the lead explanted after 3 to 4 weeks. In 90% of the patients a pacemaker is implanted after the test period, these patients will have an additional operation that could have been avoided if they had the permanent pacemaker implanted at the first stage. Hypotheses In a selected patient group suffering from faecal incontinence a one-stage permanent implant will be possible. The functional results will be improved as more time can be spent finding the optimal pacemaker settings as the risk of infection is reduced compared to the stage implant. One-Stage implantation gives the opportunity to test the amount of placebo effect with SNS. During the first 3 months postoperative patients will be randomized to either stimulation amplitude set at 90% of sensory threshold (control group) or 3 periods of stimulation at 0.05v (placebo), 50% and 90% of sensory threshold. Patients are randomized. After the initial 3 months the stimulation amplitude is increased to sensory threshold. After six months the project ends and the number of patients achieving the 50% improvement in incontinence episodes are evaluated.

Interventions

DEVICESacral nerve stimulation at different stimulation amplitudes

Exploring the effect of different stimulation amplitude in a randomized study

Sponsors

University of Tromso
CollaboratorOTHER
Hvidovre University Hospital
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Alle patients are stimulated sub-sensory in (3x4 weeks) and will be blinded. The investigators will not participate in the randomization, and setting of the stimulation amplitude.

Intervention model description

Patients will be randomized to either control group (Stimulation amplitude at 90% of sensory threshold) or intervention arm (different stimulation amplitude - 0.05 V, 50 and 90% of sensory threshold)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years * Informed consent * Idiopathic faecal incontinence or incontinence following external sphincter tear ≤ 160 degrees. * ≥ one faecal incontinence episode after optimized conservative treatment. * Ability to use the patient programmer.

Exclusion criteria

* Pregnancy * Diabetes * Neurological diseases, including spinal cord injuries * Pelvic irradiation * Rectal resections

Design outcomes

Primary

MeasureTime frameDescription
Bowel Habit Diary changes12 weeksChange in number of incontinence episodes(Bowel Habit diary - ≥50% reduction in fecal incontinence episodes), compared to baseline.

Secondary

MeasureTime frameDescription
Functional outcome measure - St. Marks incontinence score4, 8, 12, and 24 weeksChanges in St. Marks incontinence score, compared to baseline.
Quality of Life FI - specific4, 8, 12, and 24 weeksChanges in Rockwood Faecal Incontinence Quality of Life score, compared to baseline
Changes in functional outcome - Urin incontinence (UI).4, 8, 12, and 24 weeksICIQ\_UI Short form,
Functional outcome measure - Wexner Incontinence score4, 8, 12, and 24 weeksChanges in Wexner incontinence score, compared to baseline.
Visual analogue score (VAS score): patients overall satisfaction4, 8, 12, and 24 weeksVAS-score (0-100) for patients satisfaction with overall: * Social function * Bowel function * Quality of life Baseline value used as reference
Anal physiology testbaseline, 4,8,12 and 25 weeks after implantation(Only in patients implanted in Aarhus, Denmark)Functional Lumen Imaging Probe (endoFLIP) and anal sensibility. The endoFLIP allows dynamic examination of the geometry and segmental distensibility properties of the anal canal by simultaneous measurement of anal pressure(PSI) and luminal cross sectional areas (CSAs) at 16 points along the length of the anal canal
Bowel Habit Diary24 weeksChange in number of incontinence episodes(Bowel Habit diary - ≥50% reduction in fecal incontinence episodes), compared to baseline.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026